Trials / Completed
CompletedNCT02217839
Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Aspireo Pharmaceuticals Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This multi-ascending dose study is designed to investigate the safety, tolerability, pharmacokinetic and side effect profile of multiple ascending doses of DG3173, in up to 48 healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DG3173 | |
| DRUG | DG3173+Octreotide | |
| DRUG | Octreotide | |
| DRUG | DG3173 Placebo | |
| DRUG | DG3173 Placebo+Octreotide Placebo | |
| DRUG | Octreotide+DG3173 Placebo |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-01-01
- First posted
- 2014-08-15
- Last updated
- 2014-08-15
Source: ClinicalTrials.gov record NCT02217839. Inclusion in this directory is not an endorsement.